Part D Drug Pricing Change Would Affect Commercial Plans, PBMs Say
Executive Summary
The Pharmaceutical Care Management Association is arguing that CMS' plan to redefine the allowable cost for drugs will have a negative impact not only on Medicare Part D prescription plans, but on commercial plans as well